Karen Akinsanya
Director; President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships · 3 filings · Latest: Jun 18, 2026
Nautilus Biotechnology, Inc.
Schrodinger, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
SDGR | Karen Akinsanya | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Mar 5, 2026 | Sale | $12.90 | 1,366 | $17.6K | 69,956 | |
SDGR | Akinsanya Karen | — | Mar 5, 2026 | Proposed Sale | $12.90 | 1,366 | $17.6K | — | |
SDGR | Karen Akinsanya | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Mar 2, 2026 | Sale | $11.99 | 2,206 | $26.5K | 71,322 | |
SDGR | Akinsanya Karen | — | Mar 2, 2026 | Proposed Sale | $11.99 | 2,206 | $26.5K | — | |
SDGR | Karen Akinsanya | — | Apr 14, 2025 | Proposed Sale | $24.49 | 16,723 | $409.5K | — |